

Rapid Response™

Oral Fluid Lollipop Drug Test

Product Insert

A rapid test for the simultaneous, qualitative detection of multiple drugs and drug metabolites in human saliva.

For forensic use only.

Intended Use

The Rapid Response™ Oral Fluid Lollipop Drug Test is a lateral flow chromatographic immunoassay for the qualitative detection of multiple drugs and drug metabolites in saliva at the following cut-off concentrations:

Test	Calibrator	Cut-off (ng/mL)
Amphetamine (AMP)	d-Amphetamine	25/50
Barbiturates (BAR)	Secobarbital	50
Buprenorphine (BUP)	Buprenorphine	5/10
Benzodiazepines (BZO)	Oxazepam	10/20/30
Cocaine (COC)	Cocaine	10/15/20/50
Cotinine (COT)	Cotinine	30/50
Fentanyl (FYL)	Fentanyl	10
Ketamine (KET)	Ketamine	30/50
Methylenedioxymethamphetamine (MDMA)	d,l-Methylenedioxymethamphetamine	50
Methamphetamine (MET)	d-Methamphetamine	25/50
Methadone (MTD)	Methadone	30
Opiates (OPI)	Morphine	10/30/40/50
Oxycodone (OXY)	Oxycodone	20
Phencyclidine (PCP)	Phencyclidine	3/10
Propoxyphene (PPX)	d-Propoxyphene	30/50
Synthetic Marijuana (K2)	JWH-018 5-Pentanoic acid metabolite	25/30
Synthetic Marijuana (K3)	AB-PINACA Pentanoic acid metabolite	10
Marijuana (THC)	11-nor-Δ9-THC-9 COOH	12/50
Marijuana (THC)	Δ9-THC	15/40/50
Tramadol (TML)	Cis-Tramadol	30/50
Zopiclone (ZOP)	Zopiclone	20
6-Monoacetylmorphine (6-MAM)	6-Monoacetylmorphine	3/5/10
Alcohol (ALC)	Alcohol	0.02% (20mg/dL)

This assay provides only a preliminary analytical test result. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. Gas chromatography/mass spectrometry (GC/MS) and gas chromatography/tandem mass spectrometry (GC/MS/MS) are the preferred confirmatory methods. Professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated.

Summary

The Rapid Response™ Oral Fluid Lollipop Drug Test is a rapid saliva screening test that can be performed without the use of an instrument.

The test utilizes monoclonal antibodies to selectively detect elevated levels of specific drugs in human saliva.

Amphetamine (AMP)

Amphetamine is a sympathomimetic amine with therapeutic indications. The drug is often self-administered by nasal inhalation or oral ingestion. Depending on the route of administration, amphetamine can be detected in oral fluid as early as 5-10 minutes following use.¹ Amphetamine can be detected in oral fluids for up to 72 hours after use.¹

Barbiturates (BAR)

Barbiturates are central nervous system depressants. They are used therapeutically as sedatives, hypnotics, and anticonvulsants. Barbiturates are almost always taken orally as capsules or tablets. The effects resemble those of alcohol intoxication. Chronic use of Barbiturates leads to tolerance and physical dependence. Short acting Barbiturates taken at 400 mg/day for 2-3 months produce a clinically significant degree of physical dependence. A study of a single oral dose of one barbiturate: butalbital, phenobarbital or secobarbital showed the drug is detectable in oral fluid with 15-60 minutes of dosing and remained detectable in oral fluid for 52 hours.

Buprenorphine (BUP)

Buprenorphine is a potent analgesic often used in the treatment of opioid addiction. The drug is sold under the trade names Subutex™, Buprenex™, Temgesic™, and Suboxone™ which contain Buprenorphine HCl alone or in combination with Naloxone HCl. Therapeutically, Buprenorphine is used as a substitution treatment for opioid addicts. Substitution treatment is a form of medical care offered to opiate addicts (primarily heroin addicts) based on a similar or identical substance to the drug normally used. In substitution therapy, Buprenorphine is as effective as Methadone but demonstrates a lower level of physical dependence. Substantial abuse of Buprenorphine has also been reported in many countries where various forms of the drug are available. The drug has been diverted from legitimate channels through theft, doctor shopping and fraudulent prescriptions, and been abused via intravenous, sublingual, intranasal and inhalation routes.

Benzodiazepines (BZO)

Benzodiazepines are medications that are frequently prescribed for the symptomatic treatment of anxiety and sleep disorders. They produce their effects via specific receptors involving a neurochemical called gamma aminobutyric acid (GABA). Because they are safer and more effective, Benzodiazepines have replaced Barbiturates in the treatment of both anxiety and insomnia. Benzodiazepines are also used as sedatives before some surgical and medical procedures, and for the treatment of seizure disorders and alcohol withdrawal. Risk of physical dependence increases if Benzodiazepines are taken regularly (e.g. daily) for more than a few months, especially at higher than normal doses. Stopping abruptly can induce symptoms such as difficulty sleeping, gastrointestinal upset, feeling unwell, loss of appetite, sweating, trembling, weakness, anxiety and changes in perception.

Cocaine (COC)

Cocaine is a potent central nervous system (CNS) stimulant and a local anesthetic derived from the coca plant (erythroxylum coca). The drug is often self-administered by nasal inhalation, intravenous injection and free-base smoking. Depending on the route of administration, cocaine

and metabolites benzoylecgonine and ecgonine methyl ester can be detected in oral fluid as early as 5-10 minutes following use.¹ Cocaine and benzoylecgonine can be detected in oral fluids for up to 24 hours after use.¹

Cotinine (COT)

Cotinine is the first-stage metabolite of nicotine, a toxic alkaloid that produces stimulation of the autonomic ganglia and central nervous system when in humans. Nicotine is a drug to which virtually every member of a tobacco-smoking society is exposed whether through direct contact or second-hand inhalation. In addition to tobacco, nicotine is also commercially available as the active ingredient in smoking replacement therapies such as nicotine gum, transdermal patches and nasal sprays. Although nicotine is excreted in saliva, the relatively short half-life of the drug makes it an unreliable maker for tobacco use. Cotinine, however, demonstrates a substantially longer half-life than nicotine bears a high correlation with plasma cotinine levels and has been found to be the best maker for smoking status compared with saliva nicotine measurement, breath carbon monoxide testing and plasma thiocyanate testing.

Fentanyl (FYL)

Fentanyl belongs to powerful narcotics analgesics, and is a μ special opiates receptor stimulant. Fentanyl is one of the varieties that been listed in management of United Nations “Single Convention of narcotic drug in 1961”. Among the opiates agents that under international control, fentanyl is one of the most commonly used to cure moderate to severe pain. After continuous injection of fentanyl, the sufferer will have the performance of protracted opioid abstinence syndrome, such as ataxia and irritability etc., which presents the addiction after taking fentanyl in a long time. Compared with drug addicts of amphetamine, drug addicts who take fentanyl mainly have got the possibility of higher infection rate of HIV, more dangerous injection behavior and more lifelong medication overdose.

Ketamine (KET)

Ketamine is a dissociative anesthetic developed in 1963 to replace PCP (Phencyclidine). While Ketamine is still used in human anesthesia and veterinary medicine, it is becoming increasingly abused as a street drug. Ketamine is molecularly similar to PCP and thus creates similar effects including numbness, loss of coordination, sense of invulnerability, muscle rigidity, aggressive / violent behavior, slurred or blocked speech, exaggerated sense of strength, and a blank stare. There is depression of respiratory function but not of the central nervous system, and cardiovascular function is maintained. The effects of Ketamine generally last 4-6 hours following use.

Methylenedioxymethamphetamine (MDMA)

Methylenedioxymethamphetamine (Ecstasy) is a designer drug first synthesized in 1914 by a German drug company for the treatment of obesity. Those who take the drug frequently report adverse effects, such as increased muscle tension and sweating. MDMA is not clearly a stimulant, although it has, in common with amphetamine drugs, a capacity to increase blood pressure and heart rate. MDMA does produce some perceptual changes in the form of increased sensitivity to light, difficulty in focusing, and blurred vision in some users. Its mechanism of action is thought to be via release of the neurotransmitter serotonin. MDMA may also release dopamine, although the general opinion is that this is a secondary effect of the drug.⁵ The most pervasive effect of MDMA

experienced by nearly everyone who took a reasonable dose was jaw clenching.

Methamphetamine (MET)

Methamphetamine is a potent stimulant chemically related to amphetamine but with greater CNS stimulation properties. The drug is often self-administered by nasal inhalation, smoking or oral ingestion. Depending on the route of administration, methamphetamine can be detected in oral fluid as early as 5-10 minutes following use, and can be detected 72 hours after use.¹

Methadone (MTD)

Methadone is a narcotic analgesic prescribed for the management of moderate to severe pain and for the treatment of opiate dependence (heroin, Vicodin, Percocet, morphine). Methadone is a long-acting pain reliever producing effects that lasts 12-48 hours. Ideally, methadone frees the user from the burden of obtaining illegal heroin, the dangers of injection, and the emotional roller coaster that most opiates produce. Methadone, if taken for long periods and at large doses, can lead to a very long withdrawal period. The withdrawals from methadone are more prolonged and troublesome than those provoked by heroin cessation, yet the substitution and phased removal of methadone is an acceptable method of detoxification for patients and therapists.

Opiates (OPI)

The drug class opiates refers to any drug that is derived from the opium poppy, including naturally occurring compounds such as morphine and codeine, and semi-synthetic drugs such as heroin. Opiates act to control pain by depressing the central nervous system. The drugs demonstrate addictive properties when used for sustained periods of time; symptoms of withdrawal may include sweating, shaking, nausea and irritability. Opiates can be taken orally or by injection routes including intravenous, intramuscular and subcutaneous; illegal users may also take opiates intravenously or by nasal inhalation. Using an immunoassay cutoff level of 40 ng/mL, codeine can be detected in the oral fluid within 1 hour following a single oral dose and can remain detectable for 7-21 hours after the dose.² Heroin metabolite 6-monoacetylmorphine (6-MAM) is found more prevalently in excreted unmetabolized, and is also the major metabolic product of codeine and heroin.

Oxycodone (OXY)

Oxycodone is a semi-synthetic opioid with a structural similarity to codeine. The drug is manufactured by modifying thebaine, an alkaloid found in the opium poppy. Oxycodone, like all opiate agonists, provides pain relief by acting on opioid receptors in the spinal cord, brain, and possibly directly in the affected tissues. Oxycodone is prescribed for the relief of moderate to high pain under the well-known pharmaceutical trade names of OxyContin®, Tylox®, Percodan® and Percocet®. While Tylox®, Percodan® and Percocet® contain only small doses of oxycodone hydrochloride combined with other analgesics such as acetaminophen or aspirin, OxyContin consists solely of oxycodone hydrochloride in a time-release form. Oxycodone is known to metabolize by demethylation into oxymorphone and noroxycodone.

Phencyclidine (PCP)

Phencyclidine, the hallucinogen commonly referred to as Angel Dust, can be detected in saliva as a result of the exchange of the drug between the circulatory system and the oral cavity. In a paired serum and saliva

sample collection of 100 patients in an Emergency Department, PCP was detected in the saliva of 79 patients at levels as low as 2 ng/mL and as high as 600 ng/mL.⁴

Propoxyphene (PPX)

Propoxyphene (PPX) is a narcotic analgesic compound bearing structural similarity to methadone. As an analgesic, propoxyphene can be from 50-75% as potent as oral codeine. Darvocet™, one of the most common brand names for the drug, contains 50-100 mg of propoxyphene napsylate and 325-650 mg of acetaminophen. Peak plasma concentrations of propoxyphene are achieved from 1 to 2 hours post dose. In the case of overdose, propoxyphene blood concentrations can reach significantly higher levels. In humans, propoxyphene is metabolized by N-demethylation to yield norpropoxyphene. Norpropoxyphene has a longer half-life (30-36 hours) than parent propoxyphene (6-12 hours). The accumulation of norpropoxyphene seen with repeated doses may be largely responsible for resultant toxicity.

Synthetic Marijuana (K2)

Synthetic Marijuana or K2 is a psychoactive herbal and chemical product that, when consumed, mimics the effects of Marijuana. It is best known by the brand names K2 and Spice, both of which have largely become genericized trademarks used to refer to any synthetic Marijuana product. The studies suggest that synthetic marijuana intoxication is associated with acute psychosis, worsening of previously stable psychotic disorders, and may have the ability to trigger a chronic (long-term) psychotic disorder among vulnerable individuals such as those with a family history of mental illness. As of March 1, 2011, five cannabinoids, JWH-018, JWH-073, CP- 47, JWH- 200 and cannabicyclohexanol are now illegal in the US because these substances have the potential to be extremely harmful and pose an imminent hazard to public safety. The Synthetic Marijuana assay contained within the Rapid Response™ Oral Fluid Lollipop Drug Test yields a positive result when the Synthetic Marijuana metabolites concentration in saliva exceeds cut-off.

Synthetic Marijuana (K3)

Synthetic cannabinoids are designer drugs that are structurally different from THC (the active component of cannabis) but act in similar ways to affect the cannabinoid receptor system in the brain. Over the past few years, this class of designer drugs has mainstreamed to become globally popular and increasingly problematic. Synthetic cannabinoids fall into seven major structural groups:

1. Naphthoylindoles (e.g. JWH-018, JWH-073)
2. Naphthylmethylindoles (JWH-175, JWH-184, JWH-185, JWH-199)
3. Naphthoylpyrroles (JWH-145, JWH-146, JWH-147, etc.)
4. Naphthylmethylindenenes (JWH-176)
5. Phenylacetylindoles (JWH-250, JWH-251, JWH-302)
6. Cyclohexylphenols (e.g. CP 47,497)
7. Dibenzopyrans (classic cannabinoid structure such as H210 and HU-211)

New structural group: Aminoalkylindazoles (AB-PINACA, AB-FUBINACA, AB-CHMINACA, etc.)

In their original, chemical state, synthetic cannabinoids are liquid. The drugs are usually sold combined with dried herbs that emulate marijuana and are intended for smoking although powdered versions are also available. As laws are established to control these drugs with each new synthetic cannabinoid class that are introduced to the market, the older versions (JWH-018,JWH-073) are seen less frequently than before. The current trend shows the aminoalkylindazole-based drugs such as AB-

PINACA, AB-FUBINACA and AB-CHMINACA.

Marijuana (THC)

Tetrahydrocannabinol, the active ingredient in the marijuana plant (*cannabis sativa*), is detectable in saliva shortly after use. The detection of the drug is thought to be primarily due to the direct exposure of the drug to the mouth (oral and smoking administrations) and the subsequent sequestering of the drug in the buccal cavity.³ Historical studies have shown a window of detection for THC in saliva of up to 14 hours after drug use.³ The THC assay contained within the Rapid Response™ Oral Fluid Lollipop Drug Test yields a positive result when the THC-COOH concentration in oral fluid exceeds cut-off.

Tramadol (TML)

Tramadol (TML) is a quasi-narcotic analgesic used in the treatment of moderate to severe pain. It is a synthetic analog of codeine, but has a low binding affinity to the mu-opioid receptors. Large doses of tramadol can result in tolerance and physiological dependency and lead to its abuse. Tramadol is extensively metabolized after oral administration. The major pathways appear to be N- and O- demethylation, glucuronidation or sulfation in the liver.

Zopiclone (ZOP)

Zopiclone is a kind of benzodiazepines sedative hypnotics that belongs to cyclopyrrolidone. It combines with Benzodiazepine receptor in part of GABA receptor and is absorbed rapidly after oral administration and reaches peak concentration in plasma 1-1.5 hours later, with the oral bioavailability being close to 80%. 45%-80% of zopiclone binds with plasma protein and is widely distributed throughout the body. Its concentration in saliva is higher than that in plasma. Its bitter taste is proportional to the concentration in saliva. Since zopiclone was applied in clinic in 1985, its abuse and addiction tendency have been a controversial topic. Some studies have pointed out that its risk is low, however there are growing individual reports of abuse, addiction and withdrawal complications throughout different parts of the world.

6-Monoacetylmorphine (6-MAM)

6-Monoacetylmorphine (6-MAM) or 6-Acetylmorphine (6-AM) is one of three active metabolites of heroin (diacetylmorphine), the others being morphine and the much less active 3-Monoacetylmorphine (3-MAM). 6-MAM occurs as a metabolite of heroin, which is rapidly created from heroin in the body. Heroin is rapidly metabolized by esterase enzymes in the brain and has an extremely short half-life. It has also relatively weak affinity to μ-opioid receptors because the 3-hydroxy group, essential for effective binding to the receptor, is masked by the acetyl group. Therefore, heroin acts as a pro-drug, serving as a lipophilic transporter for the systemic delivery of morphine, which actively binds with μ-opioid receptors.


Alcohol (ALC)

Two-thirds of all adults drink alcohol. However, alcohol intoxication can lead to loss of alertness, coma, death and birth defects. The blood alcohol concentration (BAC) at which a person becomes impaired is variable. The United States Department of Transportation (DOT) has established a BAC of 0.02% (20mg/dL) as the cut-off level at which an individual is considered positive for the presence of alcohol. Determination of ethyl alcohol in urine, blood and saliva is commonly used for measuring legal

impairment, alcohol poisoning, etc. Gas chromatography techniques and enzymatic methods are commercially available for the determination of ethyl alcohol in human fluids.

Principle

The Rapid Response™ Oral Fluid Lollipop Drug Test for AMP/BAR/BUP/BZO/COC/COT/FYL/KET/MDMA/MET/MTD/OPI/OXY/PCP/PPX/K2/K3/THC/TML/ZOP/6-MAM is an immuno-assay based on the principle of competitive binding. Drugs that may be present in the oral fluid specimen compete against their respective drug conjugate for binding sites on their specific antibody. During testing, a portion of the oral fluid specimen migrates upward by capillary action. A drug, if present in the oral fluid specimen below its cut-off concentration, will not saturate the binding sites of its specific antibody. The antibody will then react with the drug-protein conjugate and a visible colored line will show up in the test line region of the specific drug strip. The presence of drug above the cut-off concentration in the oral fluid specimen will saturate all the binding sites of the antibody. Therefore, the colored line will not form in the test line region. A drug-positive oral fluid specimen will not generate a colored line in the specific test line region of the strip because of drug competition, while a drug-negative oral fluid specimen will generate a line in the test line region because of the absence of drug competition. To serve as a procedural control, a colored line will always appear at the control line region, indicating that proper volume of specimen has been added and membrane wicking has occurred. The Alcohol Strip (Saliva) is based on the high specificity of alcohol oxidase (ALOX) /peroxidase act on ethyl alcohol and enzyme substrate such as tetramethylbenzidine (TMB). The principle are showed below:



Reagents

The test contains membrane strips coated with drug-protein conjugates (purified bovine albumin) on the test line, a goat polyclonal antibody against gold-protein conjugate at the control line, and a dye pad which contains colloidal gold particles coated with mouse monoclonal antibody specific to Amphetamine, Methamphetamine, Cocaine, Opiates, THC-COOH, Δ9-THC, Phencyclidine, Methadone, Oxycodone, Cotinine, Methylenedioxyamphetamine, Benzodiazepines, Barbiturates, Tramadol , Zopiclone , 6-Monoacetylmorphine , Buprenorphine, Synthetic Marijuana, Synthetic Marijuana K3, Propoxyphene and Ketamine. For alcohol strip, the reagents contain Tetramethylbenzidine (TMB), Alcohol Oxidase, Peroxidase, Alcohol Oxidase and other additives.

Precautions

- Do not use after the expiration date.
- The test should remain in the sealed pouch until use.
- Saliva is not classified as biological hazard unless derived from a dental procedure.
- The used test should be discarded according to federal, state and local regulations.

Materials

Materials provided

- Lollipop tests
- Color card (for alcohol strip)

- Product insert
- Quick Reference Guide

Materials required but not provided

- Timer

Storage and Stability

Store as packaged in the sealed pouch at 36-86°F (2-30°C). The test is stable through the expiration date printed on the sealed pouch. The lollipop tests must remain in the sealed pouch until use. **DO NOT FREEZE.** Do not use beyond the expiration date.


Collection and Storage of Specimens

The oral fluid specimen should be collected using the collector provided with the kit. Follow the detailed Test Procedure below. No other collection devices should be used with this assay. Oral fluid collected at any time of the day may be used.


Test Procedure

Allow the test, specimen, and/or controls to reach room temperature (59-86°F; 15-30°C) prior to testing. Instruct the donor to not place anything in the mouth including food, drink, gum or tobacco products for at least 10 minutes prior to collection.


1. Remove the test from the sealed pouch and use it within one hour of opening.
2. Remove the cap to uncover the oral fluid collector.
3. Place the collector in your mouth. Do not let saliva touch the plastic body of the test. See illustration below. **Keep the device level and do not tilt it.** Hold it in your mouth until saliva flows across the test strips and the control lines (C) appear.
4. Remove the test from your mouth and put the cap on. Place it on a level surface and start the timer.
5. For the alcohol strip, read the result at 1-2 minutes. Compare the color of the reaction pad with the color chart to determine the relative saliva alcohol level.
6. Read the drug test results at 10 minutes. Do not read results after 20 minutes. Use the table on the device to locate each drug and its corresponding position in the results window.



Results Interpretation



- Each strip is a column labeled S# (e.g., S1, S2, etc.).
- Test lines appear in rows labeled T# (e.g., T1, T2, etc.).
- The Control line is located in the top row labeled C.



How to Read the Table:

- Find the drug name in the Table.
 - Identify the associated Strip (S#).
 - Identify the Test region (T#).
- Match the associated coordinates S#T# from the Table to find the drug's position in the Results Window.
- Identify the Control line (C) on the same Strip (S#) of the drug's position in the Results Window.

Drug Test

POSITIVE:

The **Control (C) line is present** and **NO TEST LINE** appears in the Test region (T) for the drug. A positive result indicates the drug is present above the detectable level.


NEGATIVE:

The **Control (C) line is present** and a test line appears in the Test region (T) for the drug. *Even a very faint line is considered negative.* A negative result indicates the drug is not present or is below the detectable level.

INVALID:

NO CONTROL LINE appears in the Control region (C). Do not interpret invalid test Strips (S#). Repeat with a new test if needed. Insufficient specimen volume or incorrect procedural techniques are the most likely reasons for control line failure. Review the procedure and repeat the test using a new test. If the problem persists, discontinue using the lot immediately.

Examples:



(Please refer to the Examples illustration)

Example Illustration 1: All drugs are **positive**.

Example Illustration 2: The drugs of S1T1, S2T2, S4T3, and S5T1 are positive. The rest of the drugs are **negative**.

Example Illustration 3: All drugs are **negative**.

Example Illustration 4: Negative: S1T1, S1 T2, S1T3, S2T3, S4T1, S4T3 **Positive:** S2T1, S2 T2, S4T2 **Invalid:** S3T1, S3T2, S3T3, S5T1, S5T2, S5T3.

Alcohol (ALC) Strip

Blue or green



Positive

Negative

Invalid

POSITIVE: Alcohol Strip (Saliva) produce a color change based on the presence of saliva alcohol. The color range from light blue color (0.02% (20mg/dL) to dark blue (0.30%).

NOTE: Alcohol Strip (Saliva) is very sensitive to the presence of alcohol. A blue color that is lighter than the 0.02% color pad should be interpreted as positive but less than 0.02%(20mg/dL).

NEGATIVE: Alcohol Strip (Saliva) shows no color change. It means alcohol is not detected.

INVALID: If the color pad has a blue color before applying saliva sample, do not use the test.

Quality Control

A procedural control is included in the test. A colored line appearing in the control region (C) is considered an internal procedural control. It confirms sufficient specimen volume, adequate membrane wicking.

Limitations

The Rapid Response™ Oral Fluid Lollipop Drug Test provides only a qualitative, preliminary analytical result. A secondary analytical method must be used to obtain a confirmed result. Gas chromatography/mass spectrometry (GC/MS) or gas chromatography/tandem mass spectrometry (GC/MS/MS) is preferred confirmatory methods. A positive test result does not indicate the concentration of drug in the specimen or the route of administration. A negative result may not necessarily indicate a drug-free specimen. Drug may be present in the specimen below the cutoff level of the assay.

Alcohol Strip

- The saliva sample should be collected 15 minutes after intaking food, drink, or other materials (including smoking), the residual may affect the test results.
- Some household products, such as disinfectant, deodorizers, perfumes, and glass cleaners, contain alcohol, these factors should be excluded before testing.
- Ingestion or general use of over-the-counter medications and products containing alcohol can produce positive results.

Performance Characteristics

Accuracy

Assemble each single test into the cup before testing, and evaluate the cup with approximately 44-280 specimens per drug type previously collected from subjects presenting for Drug Screen Testing which were confirmed by GC/MS. These specimens were randomized and tested using the Rapid Response™ Oral Fluid Lollipop Drug Test were rated as either positive or negative at 10 minutes. The test results are shown in table below.

Table: Specimen Correlation

Method		GC/MS		% Agreement with GC/MS	% Total agreement with GC/MS
Rapid Response™ Oral Fluid Lollipop Drug Test		Positive	Negative		
AMP 25	Positive	56	2	96.6%	97.5%
	Negative	2	100	98.0%	
AMP 50	Positive	90	6	94.7%	94.8%
	Negative	5	109	94.8%	
BAR 50	Positive	80	6	96.4%	95.7%
	Negative	3	121	95.3%	

BUP 5	Positive	86	5	95.6%	95.7%
	Negative	4	115	95.8%	
BUP 10	Positive	86	5	95.6%	95.7%
	Negative	4	115	95.8%	
BZO 10	Positive	94	5	94.0%	94.8%
	Negative	6	105	95.5%	
BZO 20	Positive	94	5	94.0%	94.8%
	Negative	6	105	95.5%	
BZO 30	Positive	94	5	94.0%	94.8%
	Negative	6	105	95.5%	
COC 10	Positive	37	3	90.2%	95.3%
	Negative	4	106	97.2%	
COC 15	Positive	41	0	>99%	>99%
	Negative	0	109	>99%	
COC 20	Positive	38	2	92.7%	96.7%
	Negative	3	107	98.2%	
COC 50	Positive	38	2	95.0%	96.7%
	Negative	3	107	97.3%	
COT 30	Positive	131	2	99.2%	98.7%
	Negative	1	96	98.0%	
COT 50	Positive	131	2	99.2%	98.7%
	Negative	1	96	98.0%	
FYL 10	Positive	53	1	93.0%	96.7%
	Negative	4	92	98.9%	
KET 30	Positive	49	3	90.7%	94.5%
	Negative	5	88	96.7%	
KET 50	Positive	90	6	94.7%	94.8%
	Negative	5	109	94.8%	
MDMA 50	Positive	96	1	97.0%	98.3%
	Negative	3	130	99.2%	
MET 25	Positive	43	2	93.5%	96.4%
	Negative	3	92	97.9%	
MET 50	Positive	126	4	99.2%	98.2%
	Negative	1	149	97.4%	
MTD 30	Positive	116	3	97.5%	97.4%
	Negative	3	108	97.3%	
OPI 30	Positive	61	3	96.8%	96.8%
	Negative	2	89	96.7%	
OPI 40	Positive	89	7	93.7%	93.8%
	Negative	6	108	93.9%	
OPI 50	Positive	89	7	93.7%	93.8%
	Negative	6	108	93.9%	
OPI 10	Positive	88	8	92.6%	92.9%
	Negative	7	107	93.0%	
OXY 20	Positive	91	1	97.8%	98.7%
	Negative	2	136	99.3%	
PCP 3	Positive	107	2	96.4%	97.4%
	Negative	4	117	98.3%	
PCP 10	Positive	107	2	96.4%	97.4%
	Negative	4	117	98.3%	
PPX 30	Positive	92	3	95.8%	96.7%
	Negative	4	111	97.4%	
PPX 50	Positive	92	3	95.8%	96.7%
	Negative	4	111	97.4%	
K2 25	Positive	52	2	92.9%	96%
	Negative	4	92	97.9%	
K2 30	Positive	52	2	96.3%	96%
	Negative	4	92	95.8%	
K3 10	Positive	4	0	>99%	>99%
	Negative	4	0	>99%	

THC 12	Negative	0	40	>99%	96.8%
	Positive	75	5	96.2%	
THC 50	Negative	3	167	97.1%	96.8%
	Positive	75	5	96.2%	
THC 15 Parent	Negative	3	167	97.1%	97.8%
	Positive	43	0	95.6%	
THC 40 Parent	Negative	2	45	>99%	98.0%
	Positive	45	0	95.7%	
THC 50 Parent	Negative	2	52	>99%	97.8%
	Positive	42	0	95.5%	
TML 50	Negative	2	48	99%	95.7%
	Positive	80	6	96.4%	
TML 30	Negative	3	121	95.3%	>99%
	Positive	89	0	>99%	
ZOP 20	Negative	0	121	>99%	>99%
	Positive	0	114	>99%	
6-MAM 3	Negative	36	0	>99%	>99%
	Positive	0	128	>99%	
6-MAM 5	Negative	36	0	>99%	>99%
	Positive	0	128	>99%	
6-MAM 10	Negative	36	0	>99%	>99%
	Positive	0	128	>99%	

Alcohol Strips

Alcohol Strip (Saliva)	Results	>0.02% (Spiked)	0	Total Results
	Positive	30	0	30
	Negative	1	29	30
Total Results		31	29	60
% Agreement		97%	100%	98%

Analytical Sensitivity

A Phosphate-buffered saline (PBS) pool was spiked with drugs to target concentrations of ±50% cut-off, ±25% cut-off and +300% cut-off and tested with the Rapid Response™ Oral Fluid Lollipop Drug Test. The results are summarized below.

Drug conc. (Cut-off range)	n	AMP25		AMP50		BAR50		BUP5	
		-	+	-	+	-	+	-	+
0% Cut-off	30	30	0	30	0	30	0	30	0
-50% Cut-off	30	30	0	30	0	30	0	30	0
-25% Cut-off	30	25	5	27	3	26	4	27	3
Cut-off	30	15	15	15	15	19	11	15	15
+25% Cut-off	30	4	26	7	23	6	24	7	23
+50% Cut-off	30	0	30	0	30	0	30	0	30
+300% Cut-off	30	0	30	0	30	0	30	0	30

Drug conc. (Cut-off range)	n	BUP10		BZO10		BZO20		BZO30	
		-	+	-	+	-	+	-	+
0% Cut-off	30	30	0	30	0	30	0	30	0
-50% Cut-off	30	30	0	30	0	30	0	30	0

-25% Cut-off	30	27	3	27	3	27	3	27	3
Cut-off	30	15	15	15	15	15	15	15	15
+25% Cut-off	30	7	23	7	23	7	23	7	23
+50% Cut-off	30	0	30	0	30	0	30	0	30
+300% Cut-off	30	0	30	0	30	0	30	0	30

Drug conc. (Cut-off range)	n	COC10		COC15		COC20		COC50	
		-	+	-	+	-	+	-	+
0% Cut-off	30	30	0	30	0	30	0	30	0
-50% Cut-off	30	30	0	30	0	30	0	30	0
-25% Cut-off	30	26	4	25	5	26	4	25	3
Cut-off	30	15	15	15	15	15	15	15	10
+25% Cut-off	30	3	27	3	27	5	25	3	26
+50% Cut-off	30	0	30	0	30	0	30	0	30
+300% Cut-off	30	0	30	0	30	0	30	0	30

Drug conc. (Cut-off range)	n	COT30		COT50		FYL10		KET30	
		-	+	-	+	-	+	-	+
0% Cut-off	30	30	0	30	0	30	0	30	0
-50% Cut-off	30	30	0	30	0	30	0	30	0
-25% Cut-off	30	27	3	28	2	24	6	28	2
Cut-off	30	20	10	16	14	15	15	15	15
+25% Cut-off	30	4	26	6	24	3	27	1	29
+50% Cut-off	30	0	30	0	30	0	30	0	30
+300% Cut-off	30	0	30	0	30	0	30	0	30

Drug conc. (Cut-off range)	n	KET50		MDMA50		MET25		MET50	
		-	+	-	+	-	+	-	+
0% Cut-off	30	30	0	30	0	30	0	30	0
-50% Cut-off	30	30	0	30	0	30	0	30	0
-25% Cut-off	30	25	5	25	5	24	6	28	2
Cut-off	30	16	14	20	10	14	16	16	14
+25% Cut-off	30	4	26	7	23	4	26	6	24
+50% Cut-off	30	0	30	0	30	0	30	0	30
+300% Cut-off	30	0	30	0	30	0	30	0	30

Drug conc. (Cut-off range)	n	MTD30		OPI10		OPI30		OPI40	
		-	+	-	+	-	+	-	+
0% Cut-off	30	30	0	30	0	30	0	30	0
-50% Cut-off	30	30	0	30	0	30	0	30	0
-25% Cut-off	30	27	3	26	4	24	6	27	3
Cut-off	30	13	17	13	17	14	16	15	15
+25% Cut-off	30	7	23	7	23	4	26	8	22
+50% Cut-off	30	0	30	0	30	0	30	0	30

+300% Cut-off	30	0	30	0	30	0	30	0	30
---------------	----	---	----	---	----	---	----	---	----

Drug conc. (Cut-off range)	n	OPI50		OXY20		PCP3		PCP10	
		-	+	-	+	-	+	-	+
0% Cut-off	30	30	0	30	0	30	0	30	0
-50% Cut-off	30	30	0	30	0	30	0	30	0
-25% Cut-off	30	27	3	25	5	26	4	24	4
Cut-off	30	15	15	15	15	14	16	14	16
+25% Cut-off	30	8	22	7	23	5	25	5	25
+50% Cut-off	30	0	30	0	30	0	30	0	30
+300% Cut-off	30	0	30	0	30	0	30	0	30

Drug conc. (Cut-off range)	n	PPX30		PPX50		K2 25		K2 30	
		-	+	-	+	-	+	-	+
0% Cut-off	30	30	0	30	0	30	0	30	0
-50% Cut-off	30	30	0	30	0	30	0	30	0
-25% Cut-off	30	25	5	25	5	26	4	26	4
Cut-off	30	15	15	15	15	15	15	15	15
+25% Cut-off	30	4	26	4	26	4	26	4	26
+50% Cut-off	30	0	30	0	30	0	30	0	30
+300% Cut-off	30	0	30	0	30	0	30	0	30

Drug conc. (Cut-off range)	n	K3 10		THC12		THC50		THC40 (Parent)	
		-	+	-	+	-	+	-	+
0% Cut-off	30	30	0	30	0	30	0	30	0
-50% Cut-off	30	30	0	30	0	30	0	30	0
-25% Cut-off	30	26	4	26	4	26	4	26	4
Cut-off	30	14	16	14	16	15	15	13	17
+25% Cut-off	30	5	25	5	25	3	27	7	23
+50% Cut-off	30	0	30	0	30	0	30	0	30
+300% Cut-off	30	0	30	0	30	0	30	0	30

Drug conc. (Cut-off range)	n	THC50 (Parent)		THC15 (Parent)		TML30		TML50	
		-	+	-	+	-	+	-	+
0% Cut-off	30	30	0	30	0	30	0	30	0
-50% Cut-off	30	30	0	30	0	30	0	30	0
-25% Cut-off	30	27	3	27	3	25	5	26	4
Cut-off	30	12	18	12	18	14	16	14	16
+25% Cut-off	30	5	25	5	25	4	26	4	26
+50% Cut-off	30	0	30	0	30	0	30	0	30
+300% Cut-off	30	0	30	0	30	0	30	0	30

Drug conc. (Cut-off range)	n	ZOP20		6-MAM 3		6-MAM 5		6-MAM 10	
		-	+	-	+	-	+	-	+

0% Cut-off	30	30	0	30	0	30	0	30	0
-50% Cut-off	30	30	0	30	0	30	0	30	0
-25% Cut-off	30	26	4	25	5	25	5	27	3
Cut-off	30	14	16	15	15	14	16	14	16
+25% Cut-off	30	4	26	4	26	4	26	4	26
+50% Cut-off	30	0	30	0	30	0	30	0	30
+300% Cut-off	30	0	30	0	30	0	30	0	30

Analytical Specificity

The following table lists the concentration of compounds (ng/mL) above which the Rapid Response™ Oral Fluid Lollipop Drug Test for AMP/BAR/BUP/BZO/COC/COT/FYL/KET/MDMA/MET/MTD/OPI/OXY/PCP/PPX/K2/K3/THC/TML/ZOP/6-MAM identified positive results at a read time of 10 minutes.

Compound	ng/mL	Compound	ng/mL
AMPHETAMINE (AMP25)			
D-Amphetamine	25	p-Hydroxyamphetamine	200
D,L-Amphetamine	500	(+)-3,4-Methylenedioxy-amphetamine (MDA)	250
L-Amphetamine	35,000		
AMPHETAMINE (AMP50)			
D-Amphetamine	50	p-Hydroxyamphetamine	400
D,L-Amphetamine	1,000	(+)-3,4-Methylenedioxyampheta mine (MDA)	500
L-Amphetamine	70,000		
BARBITURATES (BAR50)			
Amobarbital	250	Pentobarbital	70
Aprobarbital	80	Phenobarbital	30
Butabarbital	25	Secobarbital	50
Butalbital	500		
BUPRENORPHINE (BUP5)			
Norbuprenorphine	90	Buprenorphine	5
Buprenorphine-3-β-D-glucuronide	50	Norbuprenorphine-3-β-D-glucuronide	300
BUPRENORPHINE (BUP10)			
Norbuprenorphine	180	Buprenorphine	10
Buprenorphine-3-β-D-glucuronide	100	Norbuprenorphine-3-β-D-glucuronide	600
BENZODIAZEPINES (BZO10)			
Oxazepam	10	7-Amino-clonazepam	5,000
Alprazolam	100	Bromazepam	10
Chlordiazepoxide	50	Clonazepam	1,000
Desalkylflurazepam	500	Diazepam	50
Estazolam	80	Flunitrazepam	500
Furosemide	5,000	Lorazepam	700
Midazolam	1,000	Midazolam Maleate	2,500
Nefopam	1,000	Nitrazepam	25
Norchlordiazepoxide	25	Oxolinic acid	50,000
Pheniramine	50,000	Theophylline	50,000
α-Hydroxyalprazolam	50		
BENZODIAZEPINES (BZO20)			
Oxazepam	20	7-Amino-clonazepam	10,000
Alprazolam	200	Bromazepam	20
Chlordiazepoxide	100	Clonazepam	2,000
Desalkylflurazepam	1,000	Diazepam	100
Estazolam	160	Flunitrazepam	1,000

Furosemide	10,000	Lorazepam	1,400
Midazolam	2,000	Midazolam Maleate	5,000
Nefopam	2,000	Nitrazepam	50
Norchlordiazepoxide	50	Oxolinic acid	100,000
Pheniramine	100,000	Theophylline	100,000
α-Hydroxylprazolam	100		
BENZODIAZEPINES (BZO30)			
Oxazepam	30	7-Amino-clonazepam	15,000
Alprazolam	300	Bromazepam	30
Chlordiazepoxide	150	Clonazepam	3,000
Desalkylflurazepam	1,500	Diazepam	250
Estazolam	240	Flunitrazepam	1,500
Furosemide	15,000	Lorazepam	2,100
Midazolam	3,000	Midazolam Maleate	7,500
Nefopam	3,000	Nitrazepam	125
Norchlordiazepoxide	75	Oxolinic acid	150,000
Pheniramine	150,000	Theophylline	150,000
α-Hydroxylprazolam	150		
COCAINE (COC10)			
Cocaine HCl	10	EcgonineHCl	7.5
Benzoyllecgonine	10	Cocaethylene	15
COCAINE (COC15)			
Cocaine HCl	15	EcgonineHCl	12
Benzoyllecgonine	15	Cocaethylene	23
COCAINE (COC20)			
Cocaine HCl	20	EcgonineHCl	15
Benzoyllecgonine	20	Cocaethylene	30
COCAINE (COC50)			
Cocaine HCl	50	EcgonineHCl	37.5
Benzoyllecgonine	50	Ecgonine methyl ester	75
COTININE (COT30)			
(-)-Cotinine	30	(-)-Nicotine	450
COTININE (COT50)			
(-)-Cotinine	50	(-)-Nicotine	750
FENTANYL (FYL10)			
Fentanyl	10	Norfentanyl	4
Perphenazine	20,000		
KETAMINE (KET30)			
Ketamine(KET)	30	Norketamine	400
(+/-)-Chlorpheniramine	50,000	Pantoprazole Sodium	50,000
Levorphanol	50	hydromorphpne	2,500
Meperidine (Pethidine)	50,000	Promethazine	50,000
Naloxone	10,000	d-Pseudoephedrine	100,000
Naltrexone	2,500	Phencyclidine	100
EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine)	5,000	Tetrahydrozoline	5,000
Normorphine	50,000	Heroin (diacetylmorphine)	50,000
Oxymorphone	1,000	Methamphetamine Hydrochride	50,000
Pheniramine	50,000	R(-)-Methamphetamine	50,000
KETAMINE (KET50)			
Ketamine (KET)	50	Norketamine	600
(+/-) - Chlorpheniramine	85,000	Pantoprazole Sodium	85,000
Levorphanol	85	hydromorphpne	4,000
Meperidine (Pethidine)	85,000	Promethazine	85,000

Naloxone	15,000	d-Pseudoephedrine	>100,000
Naltrexone EDDP (2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine)	4,000	Phencyclidine	150
8,500		Tetrahydrozoline	8,500
Normorphine	85,000	Heroin (diacetylmorphine)	85,000
Oxymorphone	1,500	Methamphetamine Hydrochride	85,000
Pheniramine	85,000	R(-)-Methamphetamine	85,000
METHYLENEDIOXYMETHAMPHETAMINE (MDMA50)			
(±) 3,4-Methylenedioxy-methamphetamine HCl (MDMA)	50		
(±) 3,4-Methylenedioxyamphetam-ine HCl (MDA)	300		
3,4-Methylenedioxyethylamphetam-ine (MDE)	30		
L-Methamphetamine	25,000		
METHAMPHETAMINE (MET25)			
d-Methamphetamine	25	Procaine	1,000
3,4-Methylenedioxy-methamp hetamine (MDMA)	25	D,L - Methamphetamine	100
(1R,2S) - (-) Ephedrine	200	Ephedrine	200
Fenfluramine	30,000	p-Hydroxymetham-phetamine	200
I-Phenylephrine (R)- (-) - Phenylephrine	3,125	Methoxyphenamine	12,500
Mephentermine	750	Benzphetamine	12,500
L-Methamphetamine	5,000		
METHAMPHETAMINE (MET50)			
d-Methamphetamine	50	Procaine	1000
3,4-Methylenedioxy-methamp hetamine (MDMA)	50	D,L - Methamphetamine	200
(1R,2S)-(-) Ephedrine	400	Ephedrine	400
Fenfluramine	60,000	p-Hydroxymeth- amphetamine	400
I-Phenylephrine (R)-(-)- Phenylephrine	6,250	Methoxyphenamine	25,000
Mephentermine	1,500	Benzphetamine	25,000
L-Methamphetamine	10,000		
METHADONE (MTD30)			
Methadone	30	Disopyramide	5,000
Doxylamine	50,000		
OPIATES (OPI30)			
Morphine	30	Morphine 3-β-D-Glucuronide	50
Codeine	40	Normorphine	52,500
Ethylmorphine	40	Nalorphine	75,000
Hydromorphine	150	Oxymorphone	37,500
Hydrocodone	75	Thebaine	18,750
Levorphanol	600	Diacetylmorphine (Heroin)	40
Oxycodone	45,000	6-Monoacetylmorphine	100
OPIATES (OPI40)			
Morphine	40	Morphine 3-β-D-Glucuronide	70
Codeine	50	Normorphine	70,000
Ethylmorphine	50	Nalorphine	100,00

			0
Hydromorphine	200	Oxymorphone	50,000
Hydrocodone	100	Thebaine	25,000
Levorphanol	800	Diacetylmorphine (Heroin)	50
Oxycodone	60,000	6-Monoacetylmorphine	125
OPIATES (OPI50)			
Morphine	50	Morphine 3-β-D-Glucuronide	90
Codeine	65	Normorphine	90,000
Ethylmorphine	65	Nalorphine	>100,000
Hydromorphine	250	Oxymorphone	65,000
Hydrocodone	150	Thebaine	35,000
Levorphanol	1,000	Diacetylmorphine (Heroin)	65
Oxycodone	75,000	6-Monoacetylmorphine	150
OPIATES (OPI10)			
Morphine	10	Morphine 3-β-D-Glucuronide	20
Codeine	5	Normorphine	10,000
Ethylmorphine	25	Nalorphine	700
Hydromorphine	70	Dihydrocodeine	10,000
Hydrocodone	270	6-Acetylcodeine	30
Levorphanol	1,000	Diacetylmorphine (Heroin)	25
Oxymorphone	10000	6-Monoacetylmorphine	10
Oxycodone	>10,000	Thebaine	>10,000
OXYCODONE (OXY20)			
Oxycodone	20	Codeine	25,000
Oxymorphone	40	Dihydrocodeine	6,250
Levorphanol	10,000	Naloxone	5,000
Hydrocodone	1,500	Naltrexone	5,000
Hydromorphone	10,000	Thebaine	25,000
PHENCYCLIDINE (PCP3)			
Phencyclidine	3	4-Hydroxyphencyclidine	750
PHENCYCLIDINE (PCP10)			
Phencyclidine	10	4-Hydroxyphencyclidine	2500
PROPOXYPHENE (PPX30)			
D-Propoxyphene	30	D-Norpropoxyphene	30
PROPOXYPHENE (PPX50)			
D-Propoxyphene	50	D-Norpropoxyphene	50
SYNTHETIC MARIJUANA (K2 25)			
JWH-018 5-Pentanoic acid	25	MAM2201 N-Pentanoic acid	35
JWH-073 4-Butanoic acid	25	JWH-210 N-5-Carboxypentyl	210
JWH-018 4-Hydroxypentyl	210	JWH-398 N-Pentanoic acid	175
JWH-018 5-Hydroxypentyl	300	JWH-200 6-Hydroxyindole	300
JWH-073 4-Hydroxybutyl	170	JWH-073 N-2-Hydroxybutyl	500
JWH-018 N-Propanoic acid	20	JWH-019 5-Hydroxyhexyl	500
JWH-019 6-Hydroxyhexyl	500	JWH-018	42,000
JWH-122 N-4-	500	AM2201 N-(4-	350

Hydroxypentyl		hydroxypentyl)	
RCS4 N-5-Carboxypentyl	22,500	JWH-073 N-(3-hydroxybutyl)	225
SYNTHETIC MARIJUANA (K2 30)			
JWH-018 5-Pentanoic acid	30	MAM2201 N-Pentanoic acid	45
JWH-073 4-Butanoic acid	30	JWH-210 N-5-Carboxypentyl	300
JWH-018 4-Hydroxypentyl	300	JWH-398 N-Pentanoic acid	210
JWH-018 5-Hydroxypentyl	350	JWH-200 6-Hydroxyindole	360
JWH-073 4-Hydroxybutyl	200	JWH-073 N-2-Hydroxybutyl	600
JWH-018 N-Propanoic acid	25	JWH-019 5-Hydroxyhexyl	600
JWH-019 6-Hydroxyhexyl	600	JWH-018	50,000
JWH-122 N-4-Hydroxypentyl	600	AM2201 N-(4-hydroxypentyl)	420
RCS4 N-5-Carboxypentyl	27,000	JWH-073 N-(3-hydroxybutyl)	270
SYNTHETIC MARIJUANA (K3)			
AB-PINACA pentanoic acid metabolite	10	AB-PINACA N-(4-hydroxypentyl) metabolite	10
ADB-PINACA N-(4-hydroxypentyl) metabolite	15	ADB-PINACA N-(5-hydroxypentyl) metabolite	20
5-fluoro AB-PINACA N-(4-hydroxypentyl)	20	ADB-PINACA pentanoic acid metabolite	20
AB-PINACA N-(5-hydroxypentyl) metabolite	30	5-fluoro AB-PINACA	50
AB-PINACA	100	AB-FUBINACA	150
5-fluoro ADB-PINACA	250	5-chloro AB-PINACA	1000
MARIJUANA (THC12)			
11- nor -Δ9-THC-9 COOH	12	Δ9- THC	15
Cannabinol	20,000	(±)-11-Hydroxy-Δ9-THC	400
Δ8 -THC	100	(±) Δ8 -THC	40
Cannabidiol	>100,000		
MARIJUANA (THC50)			
11- nor -Δ9-THC-9 COOH	50	Δ9- THC	75
Cannabinol	80,000	(±)-11-Hydroxy-Δ9-THC	1,600
Δ8 -THC	400	(±) Δ8 -THC	200
Cannabidiol	>100,000		
MARIJUANA (THC40)(Parent)			
Δ9 -THC	40	11- nor -Δ9-THC-9 COOH	32
Cannabinol	40,000	Δ8 -THC	250
(±)-11-Hydroxy-Δ9-THC	800	(±) Δ8 -THC	80
Cannabidiol	>100,000		
MARIJUANA (THC50)(Parent)			
Δ9 -THC	50	11- nor -Δ9-THC-9	40

		COOH	
Cannabinol	50,000	Δ8 -THC	300
(±)-11-Hydroxy-Δ9-THC	1000	(±) Δ8 -THC	100
Cannabidiol	>100,000		
MARIJUANA (THC15)(Parent)			
Δ9 -THC	15	11- nor -Δ9-THC-9 COOH	12.5
Cannabinol	20,000	Δ8 -THC	100
(±)-11-Hydroxy-Δ9-THC	400	(±) Δ8 -THC	40
Cannabidiol	>100,000		
TRAMADOL (TML50)			
Cis-tramadol	50	n-Desmethyl-cis-tramadol	25
Procyclidine	5,000	Phencyclidine	10,000
d,l-O-Desmethyl venlafaxine	25,000	o-Desmethyl-cis-tramadol	2,500
TRAMADOL (TML30)			
Cis-tramadol	30	n-Desmethyl-cis-tramadol	15
Procyclidine	3,000	Phencyclidine	6,000
d,l-O-Desmethyl venlafaxine	15,000	o-Desmethyl-cis-tramadol	1,500
ZOPICLONE (ZOP20)			
Zopiclone	20		
6-MONOACETYLMORPHINE(6-MAM 3)			
6-Monoacetylmorphine	3	Diacetylmorphine (herion)	10
6-MONOACETYLMORPHINE(6-MAM 5)			
6-Monoacetylmorphine	5	Diacetylmorphine (herion)	15
6-MONOACETYLMORPHINE(6-MAM10)			
6-Monoacetylmorphine	10	Diacetylmorphine (herion)	25

The following substances may interfere with Alcohol Strip (Saliva):

Strong oxidizers	Ascorbic acid	Tannic acid	Polyphenolic compounds
Mercaptans	Oxalic acid	Billirubin	Uric acid

Cross-Reactivity

A study was conducted to determine the cross-reactivity of the test with compounds spiked into drug-free PBS stock. The following compounds demonstrated no false positive results on the Rapid Response™ Oral Fluid Lollipop Drug Test when tested with at concentrations up to 10 µg/mL.

Acetaminophen	Acetophenetidin	N-Acetylprocainamide
Acetylsalicylic acid	Aminopyrine	Amoxicillin
Ampicillin	I-Ascorbic acid	Aspartame
Atropine	Benzilic acid	Benzoic acid
d/l-Brompheniramine	Caffeine	Chloral-hydrate
Chloramphenicol	Chlorothiazide	Cortisone
Chlorpromazine	Chloroquine	Cholesterol
Creatinine	Deoxycorticosterone	Diclofenac
Diflunisal	Digoxin	Diphenhydramine
l(-)-Epinephrine	Erythromycin	β-Estradiol
Estrone-3-sulfate	Ethyl-p-aminobenzoate	Fenoprofen
Gentisic acid	Hydralazine	p-Hydroxytyramine
Hydrochlorothiazide	o-Hydroxyhippuric acid	Hydrocortisone

Ibuprofen	d/l-Isoproterenol	Isoxsuprine
Iproniazid	Ketoprofen	Labetalol
Loperamide	Meprobamate	Methylphenidate
Nalidixic acid	Naproxen	Niacinamide
Norethindrone	Nifedipine	d/l-Octopamine
Oxalic acid	Oxymetazoline	Penicillin-G
Papaverine	Phenelzine	Phenylpropanolamine
Trans-2-phenylcyclopropylamine hydrochloride	Prednisolone	Prednisone
d/l-Propranolol	d-Pseudoephedrine	Quinacrine
Quindine	Quinine	Ranitidine
Salicylic acid	Serotonin	Sulfamethazine
Sulindac	Tetracycline	Tetrahydrocortisone3-acetate
Tetrahydrocortisone3-(β-D-glucuronide)	Thiamine	Tolbutamide
Triamterene	Trifluoperazine	d/l-Tryptophan
Tyramine	d/l-Tyrosine	Uric acid
Verapamil	Zomepirac	

Bibliography

1.

Moolchan, E., et al, “Saliva and Plasma Testing for Drugs of Abuse: Comparison of the Disposition and Pharmacological Effects of Cocaine”, Addiction Research Center, IRP, NIDA, NIH, Baltimore, MD. As presented at the SOFT-TIAFT meeting October 1998.
2.

Kim, I, et al, “Plasma and oral fluid pharmacokinetics and pharmacodynamics after oral codeine administration”, *ClinChem*, 2002 Sept.; 48 (9), pp 1486-96.
3.

Schramm, W. et al, “Drugs of Abuse in Saliva: A Review,” *J Anal Tox*, 1992 Jan-Feb; 16 (1), pp 1-9.
4.

McCarron, MM, et al, “Detection of Phencyclidine Usage by Radioimmunoassay of Saliva,” *J Anal Tox*. 1984 Sep-Oct.; 8 (5), pp 197-201.
5.

Nichols, DE, Oberlender, R. "Structure-activity relationships of MDMA and related compounds: a new class of psychoactive drugs?". *Ann N Y Acad Sci*. 1990 (600), pp 613-625.

Glossary of Symbols



Consult instructions for use



Tests per Kit



Manufacturer



Store between 36°F to 86°F



Use by



Do Not Reuse



Lot Number



Catalogue #



BTNX Inc.
722 Rosebank Road,
Pickering, ON L1W 4B2
Canada

Technical Support: 1-888-339-9964



BTNX INC.